Vor Bio: RemeGen Achieves Primary Endpoint In Phase 3 Study In China Evaluating Telitacicept
(RTTNews) - Vor Bio (VOR) announced that its collaborator, RemeGen, achieved the primary endpoint in a Phase 3 clinical study in China evaluating telitacicept in adults with primary Sjgren's disease. The study achieved the primary endpoint of improving disease activity measured by a reduction in EULAR Sjgren's syndrome disease activity index. Telitacicept demonstrated a favorable safety profile.
RemeGen plans to submit a Biologics License Application to the Center for Drug Evaluation of the National Medical Products Administration in China for primary Sjgrens disease.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.